ANKRD55 is a key regulator of T cell inflammation in multiple sclerosis

Chuyu Wu, Meiling Jiang, Xueli Yang, Yixuan Liu, Bin Huang, Yi Guo, Runjing Cao, Zhihui Cui, Guofu Deng, Weiyan Wang, Mengdi Guo, Zhiyong Lin, Jiahui Fan, Lin-Ming Zhang, Lorenzo Di Cesare Mannelli, Tao Pang, Chenhui Wang, Cun-Jin ZhangJournal of Clinical Investigation 2025 · DOI

TL;DR

Researchers have identified ANKRD55 as a crucial protein in regulating T cell inflammation, a key driver of multiple sclerosis (MS). By disrupting ANKRD55, they significantly reduced disease severity in an animal model, suggesting ANKRD55 as a promising therapeutic target for MS and other autoimmune diseases.

What Problem Does This Paper Address?

Multiple sclerosis (MS) is a debilitating autoimmune disease where the immune system mistakenly attacks the central nervous system, leading to inflammation, demyelination, and nerve damage. While T cells, particularly CD4+ T cells, are known to be central players in this inflammatory process, effectively targeting them for therapeutic intervention has been a significant challenge. The precise molecular mechanisms that govern the activation and pathogenic behavior of these T cells in MS are not fully understood, leaving a gap in developing precise treatments. This paper aims to identify key regulators of T cell function in MS pathogenesis and explore their therapeutic potential.

Methods

The researchers employed a multi-pronged approach:

  • Single-cell transcriptomic analysis: They analyzed the gene expression profiles of individual cells from cerebrospinal fluid (CSF) and blood of MS patients to identify potential key regulators.
  • Animal models: They utilized the experimental autoimmune encephalomyelitis (EAE) model, a standard animal model for MS, to study the role of ANKRD55 in disease development. This involved generating genetically modified mice with ANKRD55 deficiency (knockout mice) and T cell-specific ANKRD55 deficiency.
  • Immunoblotting and flow cytometry: These techniques were used to quantify protein and cell population levels, respectively, to assess ANKRD55 expression and the impact of its deficiency on immune cell subsets and cytokine production.
  • Molecular interaction studies: Co-immunoprecipitation (co-IP), proximity ligation assay (PLA), and immunofluorescence imaging were used to investigate how ANKRD55 interacts with other proteins, particularly components of the chaperonin-containing TCP1 (CCT) complex.
  • Cellular assays: Assays were performed to evaluate T cell activation, proliferation, and immune synapse formation.

Datasets

  • GEO database (GSE138266): Single-cell transcriptomic data from CSF and blood of MS patients and healthy controls were used for initial analysis.
  • Human PBMCs: Samples from individuals with different genotypes of the ANKRD55 gene (rs6859219) were analyzed.

Key Insights and Ideas

  • ANKRD55 as a T cell regulator: The study pinpoints ANKRD55 as a critical regulator of T cell function, particularly CD4+ T cells, which are central to MS pathogenesis.
  • ANKRD55's role in Th1/Th17 differentiation: The protein is essential for the development of Th1 and Th17 cells, known drivers of inflammation in MS.
  • Disruption of TCR signaling: ANKRD55 deficiency leads to impaired T cell receptor (TCR) signaling, a fundamental process for T cell activation.
  • Immune synapse formation: ANKRD55 is crucial for the proper formation of the immune synapse, the specialized interface where T cells interact with antigen-presenting cells.
  • Interaction with CCT complex: ANKRD55 interacts with subunits of the chaperonin-containing TCP1 (CCT) complex, which is involved in protein folding and microtubule dynamics, essential for immune synapse function.
  • Therapeutic potential: The findings strongly suggest ANKRD55 as a promising therapeutic target for MS and other autoimmune diseases driven by pathogenic T cells.

Key Results

  • ANKRD55 expression was significantly elevated in CSF and blood cells of MS patients compared to healthy controls.
  • Genetic ablation of ANKRD55 in mice led to a robustly reduced disease severity and neuroinflammation in the EAE model.
  • T cell-specific deficiency of ANKRD55 significantly impaired Th1 and Th17 cell polarization and reduced EAE pathogenicity.
  • ANKRD55 deficiency disrupted TCR signaling integrity, affecting the phosphorylation of key signaling molecules like LCK and CD3ζ.
  • ANKRD55 was found to interact with multiple subunits of the CCT complex, including TCP1, CCT3, CCT4, CCT6, and CCT7.
  • ANKRD55 appears to regulate CCT complex assembly by competing with CCT5 for binding to TCP1, CCT3, and CCT6, thereby promoting proper microtubule organization and immune synapse formation.
  • Knockdown of ANKRD55 or TCP1 significantly inhibited immune synapse formation.
  • Overexpression of ANKRD55 in Jurkat cells enhanced IL-2 production and TCR signaling activation.

Limitations and Future Work

  • Mechanism of CCT assembly: While the study demonstrates ANKRD55's role in CCT complex assembly and its competition with CCT5, the precise details of this mechanism require further investigation.
  • ANKRD55 in other autoimmune diseases: The paper notes that the role of ANKRD55 in other autoimmune conditions warrants further study.
  • Targeted interventions: The authors suggest that small-molecule inhibitors targeting the ANKRD55-CCT interaction or agents regulating tubulin polymerization could be promising therapeutic strategies. This opens avenues for developing novel treatments for autoimmune diseases.

Summary updated

Abstract

Multiple sclerosis (MS) is a progressive, chronic, and highly disabling neuroinflammatory disorder characterized by demyelination and T cell-driven inflammation. Pathogenic T cells play a central role in MS, but effective therapeutic targeting remains challenging. Here, we identified ankyrin repeat domain-containing protein 55 (ANKRD55) as a key regulator of T cell function by single-cell transcriptomic analysis of cerebrospinal fluid and blood from MS patients. ANKRD55 was predominantly expressed in CD4+ T cells in both compartments. Genetic ablation of Ankrd55 led to a robustly reduced disease severity and neuroinflammation in experimental autoimmune encephalomyelitis (EAE), a widely used animal model for MS. Furthermore, T cell-specific deficiency of Ankrd55 significantly impaired Th1 polarization and Th17 differentiation, reducing EAE pathogenicity. Mechanistically, we found that Ankrd55 deficiency disrupted T cell receptor (TCR) signaling integrity. We demonstrated that ANKRD55 regulates the formation of the immune synapse, an essential prerequisite for TCR activation, by interacting with subunits of the chaperonin-containing TCP1 (CCT) complex and modulating its activity, enhancing its assembly by competing with CCT5 for binding to TCP1, CCT3, and CCT6. This facilitates proper microtubule organization and TCR activation. These findings establish ANKRD55 as a critical regulator of TCR signaling and highlight its therapeutic potential in pathogenic T cell-driven autoimmune diseases.
BibTeX
@article{wu2025ankrd,
  author = {Chuyu Wu and Meiling Jiang and Xueli Yang and Yixuan Liu and Bin Huang and Yi Guo and Runjing Cao and Zhihui Cui and Guofu Deng and Weiyan Wang and Mengdi Guo and Zhiyong Lin and Jiahui Fan and Lin-Ming Zhang and Lorenzo Di Cesare Mannelli and Tao Pang and Chenhui Wang and Cun-Jin Zhang},
  title = {{ANKRD55 is a key regulator of T cell inflammation in multiple sclerosis}},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci195214},
}
Figure